236 related articles for article (PubMed ID: 35466792)
1. Targeted Protein Degradation: An Important Tool for Drug Discovery for "Undruggable" Tumor Transcription Factors.
Dai M; Radhakrishnan S; Li R; Tan R; Yan K; Fan G; Liu M
Technol Cancer Res Treat; 2022; 21():15330338221095950. PubMed ID: 35466792
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
3. Current strategies and progress for targeting the "undruggable" transcription factors.
Zhuang JJ; Liu Q; Wu DL; Tie L
Acta Pharmacol Sin; 2022 Oct; 43(10):2474-2481. PubMed ID: 35132191
[TBL] [Abstract][Full Text] [Related]
4. [Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy].
Wu X; Zhao J; Gao Y; Yao Q; Xie J
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3628-3643. PubMed ID: 37805843
[TBL] [Abstract][Full Text] [Related]
5. Advances in targeting 'undruggable' transcription factors with small molecules.
Henley MJ; Koehler AN
Nat Rev Drug Discov; 2021 Sep; 20(9):669-688. PubMed ID: 34006959
[TBL] [Abstract][Full Text] [Related]
6. The state of the art of PROTAC technologies for drug discovery.
Wang C; Zheng C; Wang H; Zhang L; Liu Z; Xu P
Eur J Med Chem; 2022 May; 235():114290. PubMed ID: 35307618
[TBL] [Abstract][Full Text] [Related]
7. Reimagining Druggability Using Chemoproteomic Platforms.
Spradlin JN; Zhang E; Nomura DK
Acc Chem Res; 2021 Apr; 54(7):1801-1813. PubMed ID: 33733731
[TBL] [Abstract][Full Text] [Related]
8. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer.
Lu Y; Yang Y; Zhu G; Zeng H; Fan Y; Guo F; Xu D; Wang B; Chen D; Ge G
Int J Biol Sci; 2023; 19(11):3360-3382. PubMed ID: 37496997
[TBL] [Abstract][Full Text] [Related]
9. Protein degradation technology: a strategic paradigm shift in drug discovery.
Li H; Dong J; Cai M; Xu Z; Cheng XD; Qin JJ
J Hematol Oncol; 2021 Sep; 14(1):138. PubMed ID: 34488823
[TBL] [Abstract][Full Text] [Related]
10. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
11. Targeting the undruggables-the power of protein degraders.
Zhang C; Liu Y; Li G; Yang Z; Han C; Sun X; Sheng C; Ding K; Rao Y
Sci Bull (Beijing); 2024 Mar; ():. PubMed ID: 38614856
[TBL] [Abstract][Full Text] [Related]
12. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
[TBL] [Abstract][Full Text] [Related]
13. Key Considerations in Targeted Protein Degradation Drug Discovery and Development.
Qin L; Dai H; Wang J
Front Chem; 2022; 10():934337. PubMed ID: 35978859
[TBL] [Abstract][Full Text] [Related]
14. Emerging New Concepts of Degrader Technologies.
Ding Y; Fei Y; Lu B
Trends Pharmacol Sci; 2020 Jul; 41(7):464-474. PubMed ID: 32416934
[TBL] [Abstract][Full Text] [Related]
15. Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.
Barghout SH
Anticancer Agents Med Chem; 2021; 21(2):214-230. PubMed ID: 32275492
[TBL] [Abstract][Full Text] [Related]
16. A new avenue for molecular glues: Rapid discovery of a NFKB1 degrader.
Fan AT; Boyle BT; Ferguson FM
Cell Chem Biol; 2023 Apr; 30(4):340-342. PubMed ID: 37084716
[TBL] [Abstract][Full Text] [Related]
17. Targeted protein degradation: expanding the toolbox.
Schapira M; Calabrese MF; Bullock AN; Crews CM
Nat Rev Drug Discov; 2019 Dec; 18(12):949-963. PubMed ID: 31666732
[TBL] [Abstract][Full Text] [Related]
18. Monitoring and deciphering protein degradation pathways inside cells.
Daniels DL; Riching KM; Urh M
Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
[TBL] [Abstract][Full Text] [Related]
19. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.
Hyun S; Shin D
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830024
[TBL] [Abstract][Full Text] [Related]
20. Small-Molecule PROTACs for Cancer Immunotherapy.
Liu Z; Zhang Y; Xiang Y; Kang X
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
